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Estrogens and Human Scalp Hair Growth—Still More
Questions than Answers
To the Editor:
While it is undisputed that estrogens (17-b-estradiol, E2) can
profoundly modulate hair growth in practically all mamma-
lian species investigated, usually exhibiting hair growth
inhibitory properties (Emmens, 1942; Williams et al, 1946;
Stumpf et al, 1974; Ebling et al, 1991; Smart et al, 1999;
Chanda et al, 2000), it is still rather unclear what exactly E2
administration does to human scalp hair growth.
Given the profound clinical relevance of this question and
the frequent use of E2-containing topical preparations in
trichological practise (Sinclair, 1999; Sterry and Paus, 2000),
this question deserves a more careful and more systematic
dissection than it has experienced in the past. This letter
calls attention to a few salient points that should be taken
into account in this respect.
For human scalp hair, topical E2 has long been used in
the management of telogen effluvium and androgenetic
alopecia, especially in women (Wu¨stner and Orfanos, 1974;
Schuhmacher-Stock, 1981; Sterry and Paus, 2000). Even
though this remains to be unequivocally proven in vivo, it is
felt that E2 inhibits hair shaft formation, thus lowering the
rate of hair growth, i.e., how much new hair shaft is
generated by the anagen hair bulb per time unit, yet
prolongs anagen duration, thus decreasing the telogen rate
(Schuhmacher-Stock, 1981; Sinclair et al, 1999). This would
help to explain the clinical observation that topical E2 or
high systemic E2 levels during estrogen-based contracep-
tion and during pregnancy increase the telogen/anagen ratio,
thus notably improving a pre-existing telogen effluvium,
while causing a telogen effluvium postpartum supposedly
due to E2 withdrawal (Lynfield, 1960; Barman et al, 1969;
Ebling et al, 1991). In view of the very complex, multiple
concomitant endocrine changes during and after pregnancy
and lactation (including, e.g., dramatic fluctuations in gesta-
gen and prolactin levels (Braunstein, 2003)), it is however
exceedingly difficult to dissociate strictly E2-based hair
growth effects from those that other hormones might exert
on the human scalp hair follicle in vivo during this time.
Therefore, it is reasonable to explore the isolated effects
of E2 on human hair shaft elongation, anagen duration, and
hair follicle keratinocyte proliferation/apoptosis in micro-
dissected human anagen VI scalp hair follicles that are
organ-cultured according to the method pioneered by
Philpott et al (1990)—in the absence of the sebaceous
gland, a key compartment for steroid hormone synthesis
and metabolism (Zouboulis, 2000). We found only two
corresponding reports in the published literature, one using
human anagen hair follicles from an unspecified scalp skin
location of what appears to be two male individuals aged 17
and 35 y (Kondo et al, 1990), and one recent meeting
abstract based on the use of female occipital scalp skin
follicles (Nelson et al, 2003). Both studies report that E2
(Kondo et al: 18 nM; Nelson et al: 10 nM), significantly
inhibits human scalp hair shaft elongation in vitro. In
addition, Kondo et al (1990) report that E2 does not
influence the ‘‘decay rate’’ of organ-cultured human anagen
hair follicles (as measured by morphology and autoradio-
graphic 3H-thymidine incorporation).
Recently, we have also studied the effects of E2 (1 nM–
1 mM, Sigma St. Louis, MO) on female occipital scalp hair
follicles, and have essentially confirmed hair shaft elonga-
tion-inhibitory properties of E2, which were maximal at 1 mM
(Ohnemus et al, 2003). In view of the extreme dependence
of androgen effects on the exact integumental location of
human hair follicles however (Ebling, 1991; Jahoda and
Reynolds, 1996), we were curious to learn whether E2
effects on human scalp hair follicles are location- and/or
sex-dependent. This has already been demonstrated for the
E2 response of pelage hair follicles from mice and rats,
which is profoundly influenced by sex and body site
(Emmens, 1942; Mohn, 1958).
Therefore, we have investigated in a single, large, fronto-
temporal scalp skin sample (healthy male individual, no
medications, 46 y; obtained with informed consent during
routine facelift plastic surgery; all experiments were per-
formed in order to the Declaration of Helsinki Principles)
how E2 addition to the medium (1–100 nM, Sigma, diluted
in serum-free William’s E medium, supplemented with L-
glutamine, penicillin, streptomycin, insulin, and hydrocorti-
sone) affected hair shaft elongation, anagen duration, hair
follicle pigmentation and hair matrix keratinocyte prolifera-
tion in microdissected, organ-cultured male anagen VI hair
follicles from the frontotemporal scalp skin region.
Surprisingly, compared to the vehicle control, the hair
shaft elongation of male frontotemporal scalp hair follicles
was significantly stimulated by 1–100 nM E2 already as early
as 1 d after the start of organ culture, and this stimulation
became even more pronounced at the end of organ culture
(days 7 and 9) (Fig 1). This stimulation of hair shaft formation
(which is the result of stringently coordinated proliferation
and differentiation of hair matrix keratinocytes (Stenn and
Paus, 2001) corresponded to a significant stimulation of hair
matrix keratinocyte proliferation by 10 nM E2 at day 9
(average number of Ki-positive-cells: in the control group 14
cells (SEM 3.21) and 26 cells in the E2-treated (10 nM) group
(SEM 4.38); level of significance: pp0.05, Mann–Whitney
test). While no evident differences were noted by H&E or
Abbreviations: E2, 17-b-estradiol; ER, estrogen receptor; ER-a,
estrogen receptor type alpha; ER-b, estrogen receptor type beta
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Fontana–Masson histochemistry between E2- and vehicle-
treated hair follicles in the hair follicle pigmentary unit or in
the degree of hair follicle degeneration during organ culture
(data not shown), a slight, though not statistically significant,
anagen-prolonging effect of E2 was seen in E2-treated test hair
follicles as compared to vehicle controls (data not shown).
Therefore, organ-cultured male frontotemporal scalp hair
follicles in vitro respond to E2 treatment (by a mode of E2
administration that mimics systemic drug application) with a
stimulation of both hair shaft generation and of hair matrix
keratinocyte proliferation, and a tendency towards anagen
prolongation, while no hair pigmentation effects are seen.
This is well in line with the ill-documented, but widely shared
clinical experience of topically applied E2 on the male scalp
in vivo (i.e., hair growth stimulation; Schumacher-Stock,
1981) and supports the anagen-prolonging effect of E2.
Our observation in a single, yet carefully analyzed male
patient raises five basic questions that must be addressed
much more systematically by subsequent work on the
effects of E2 on human hair growth in order to better explain
the seemingly contradictory results obtained with occipital
(Kondo et al, 1990; Nelson et al, 2003) versus frontotempor-
al scalp hair follicles (Fig 1):
1. What are the differences between male and female hair
follicles with respect to estrogen receptor (ER-a, ER-b)
expression (Thornton, 2003) and aromatase activity
(Sawaya and Price, 1997; Hoffmann, 2001, 2002)?
2. How do occipital and frontotemporal hair follicles, as well
as various other integumental sites, differ from each
other in this respect?
3. Is there any indication that E2 exerts similarly ‘‘paradox-
ical, site-dependent’’ effects on human hair growth as
androgens (Jahoda and Reynolds, 1996)? Does the
signalling and gene expression response of a defined
human hair follicle population to E2 stimulation differ in a
stringently location-dependent manner, as has been
postulated, e.g., for the response of beard hair versus
scalp follicles to androgen stimulation with respect to
TGFb1 expression in the dermal papilla (Inui et al, 2002)?
4. Which important regional differences in the extrafollicular
estrogen metabolism of defined integumental sites must be
taken into account when estrogens are administered topi-
cally (e.g., with respect to epidermal, sebaceous, and
dermal activities of key enzymes like aromatase, 17b-
hydroxysteroid dehydrogenase, or steroid sulfatase)?
5. How is ER expression and/or the metabolism of topically
applied estrogens in loco influenced by the choice of
vehicle?
Only when these basic questions are finally addressed
systematically can we expect to solve the ancient enigma of
what estrogens really do to human hair growth in a defined
integumental site in vivo, on the scalp and elsewhere, and
can rationally select estrogen receptor ligands for thera-
peutically desired hair growth modulation.
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Figure 1
Hair shaft elongation of organ-cultured human scalp hair follicles
(%, male, frontotemporal), measurements of the increase of the length
of the follicles on days 0, 1, 3, 5, 7, and 9 (compared to day 0), using
an inverted microscope fitted with an eyepiece measuring graticule
SEM, Level of significance: pp0.05; pp0.01; pp0.001. Mann–
Whitney test, test groups are compared to the vehicle control. n¼36
hair follicles per test group, n¼18 hair follicles in the control group.
Note added in proof: The stimulation of male frontotemporal
hair follicles by E2 reported here (Fig 1) was just confirmed by us
using frontotemporal hair follicles from a second male patient.
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